Codexis/$CDXS
1D1W1MYTD1Y5YMAX
Capital at risk
About Codexis
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
- Ticker
- $CDXS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 146
- Headquarters
- Redwood City, United States
- Website
- www.codexis.com
Codexis Metrics
BasicAdvanced
$160M
-
-$0.34
2.50
-
Price and volume
Market cap
$160M
Beta
2.5
52-week high
$2.98
52-week low
$0.96
Average daily volume
1M
Financial strength
Current ratio
3.059
Quick ratio
2.831
Long term debt to equity
188.834
Total debt to equity
220.241
Interest coverage (TTM)
-4.68%
Profitability
EBITDA (TTM)
-19.047
Gross margin (TTM)
24.27%
Net profit margin (TTM)
-39.55%
Operating margin (TTM)
-31.23%
Effective tax rate (TTM)
-0.23%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
-11.74%
Return on equity (TTM)
-69.36%
Valuation
Price to revenue (TTM)
1.71
Price to book
4.06
Price to tangible book (TTM)
4.39
Price to free cash flow (TTM)
-10.903
Free cash flow yield (TTM)
-9.17%
Free cash flow per share (TTM)
-0.134
Growth
Revenue change (TTM)
35.89%
Earnings per share change (TTM)
-58.11%
3-year revenue growth (CAGR)
-7.81%
10-year revenue growth (CAGR)
3.90%
3-year earnings per share growth (CAGR)
-26.63%
10-year earnings per share growth (CAGR)
24.84%
What the Analysts think about Codexis
Analyst ratings (Buy, Hold, Sell) for Codexis stock.
Analyst projections of the future price of Codexis stock.
Codexis Financial Performance
Revenues and expenses
Codexis Earnings Performance
Company profitability
Upcoming events
No upcoming events
Codexis News
AllArticlesVideos
Funds containing Codexis
AllUSDGBPEUR
Fund name | Fund size | $CDXS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.